Synaptic Dysfunction in 4R-Tauopathies Comparison

📖 Wiki Page

disease1990 wordssynced 2026-04-02

Synaptic Dysfunction in 4R-Tauopathies Comparison

4R-Tauopathies are a group of neurodegenerative disorders characterized by the accumulation of 4-repeat tau protein isoforms in the brain. This comparison examines synaptic dysfunction across five major 4R-tauopathies: [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-degeneration) (CBD), [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease) (AGD), [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy) (GGT), and [FTDP-17](/diseases/ftdp-17) (Frontotemporal Dementia with Parkinsonism-17).

Overview

flowchart TD A["4R-Tauopathies"] --> B["PSP"] A --> C["CBD"] A --> D["AGD"] A --> E["GGT"] A --> F["FTDP-17"] B --> G1["Synaptic Loss"] C --> G2["Synaptic Loss"] D --> G3["Synaptic Loss"] E --> G4["Synaptic Loss"] F --> G5["Synaptic Loss"] G1 --> H["Basal Ganglia<br/>Cortical"] G2 --> H G3 --> H G4 --> H G5 --> H H --> I["Dopaminergic"] H --> J["GABAergic"] H --> K["Glutamatergic"] H --> L["Cholinergic"] style A fill:#3b1114,color:#e0e0e0 style G1 fill:#3b1114,color:#e0e0e0 style G2 fill:#3b1114,color:#e0e0e0 style G3 fill:#3b1114,color:#e0e0e0 style G4 fill:#3b1114,color:#e0e0e0 style G5 fill:#3b1114,color:#e0e0e0

...

Synaptic Dysfunction in 4R-Tauopathies Comparison

Overview

Mermaid diagram (expand to render)

Synaptic dysfunction is a central pathological feature across all 4R-tauopathies, though the pattern and severity vary considerably between diseases. Research demonstrates that synaptic loss correlates strongly with cognitive and motor impairments in these disorders, often preceding overt neuronal death.

Synaptic Protein Loss Patterns

| Protein Category | PSP | CBD | AGD | GGT | FTDP-17 |
|-----------------|-----|-----|-----|-----|---------|
| Synaptophysin | Severe ↓ (50-70%) | Moderate-severe ↓ (40-60%) | Mild-moderate ↓ (20-40%) | Severe ↓ (50-70%) | Severe ↓ (60-80%) |
| Synapsin I | Moderate ↓ (30-50%) | Moderate ↓ (30-50%) | Mild ↓ (10-30%) | Severe ↓ (50-70%) | Moderate-severe ↓ (40-60%) |
| PSD-95 | Severe ↓ (60-80%) | Moderate-severe ↓ (40-70%) | Moderate ↓ (30-50%) | Severe ↓ (60-80%) | Severe ↓ (70-90%) |
| Synaptopodin | Moderate ↓ (30-50%) | Moderate ↓ (30-50%) | Mild ↓ (15-30%) | Severe ↓ (50-70%) | Moderate-severe ↓ (40-60%) |
| Rab3A | Moderate ↓ (30-50%) | Moderate ↓ (20-40%) | Mild ↓ (10-25%) | Severe ↓ (40-60%) | Moderate ↓ (30-50%) |

Regional Patterns of Synaptic Loss

| Brain Region | PSP | CBD | AGD | GGT | FTDP-17 |
|-------------|-----|-----|-----|-----|---------|
| Basal Ganglia | Severe | Severe | Moderate | Severe | Moderate |
| Motor Cortex | Moderate | Severe | Mild | Moderate | Moderate |
| Frontal Cortex | Moderate | Severe | Moderate | Severe | Severe |
| Temporal Cortex | Mild-moderate | Moderate | Moderate | Moderate | Severe |
| Parietal Cortex | Mild | Moderate | Mild-moderate | Moderate | Moderate |
| Brainstem | Severe | Moderate | Moderate | Severe | Moderate |
| Cerebellum | Mild | Mild | Mild | Moderate | Mild |

Neurotransmitter Receptor Changes

Glutamate Receptors

| Receptor | PSP | CBD | AGD | GGT | FTDP-17 |
|----------|-----|-----|-----|-----|---------|
| NMDA (NR1) | ↓ 30-50% | ↓ 40-60% | ↓ 15-30% | ↓ 50-70% | ↓ 40-60% |
| AMPA (GluA1-3) | ↓ 20-40% | ↓ 40-60% | ↓ 10-25% | ↓ 40-60% | ↓ 30-50% |
| mGluR1 | ↓ 20-35% | ↓ 30-50% | ↓ 10-20% | ↓ 40-60% | ↓ 25-40% |
| mGluR5 | ↓ 15-30% | ↓ 25-45% | ↓ 10-20% | ↓ 30-50% | ↓ 20-40% |

GABA Receptors

| Receptor | PSP | CBD | AGD | GGT | FTDP-17 |
|----------|-----|-----|-----|-----|---------|
| GABA-A (α1) | ↓ 30-50% | ↓ 40-60% | ↓ 15-30% | ↓ 40-60% | ↓ 35-55% |
| GABA-A (α5) | ↓ 40-60% | ↓ 50-70% | ↓ 20-40% | ↓ 50-70% | ↓ 45-65% |
| GABA-B | ↓ 25-45% | ↓ 35-55% | ↓ 15-30% | ↓ 40-60% | ↓ 30-50% |

Dopamine Receptors

| Receptor | PSP | CBD | AGD | GGT | FTDP-17 |
|----------|-----|-----|-----|-----|---------|
| D1 (D1R) | ↓ 40-60% | ↓ 20-40% | ↓ 10-25% | ↓ 30-50% | ↓ 30-50% |
| D2 (D2R) | ↓ 50-70% | ↓ 30-50% | ↓ 15-30% | ↓ 40-60% | ↓ 40-60% |

Acetylcholine Receptors

| Receptor | PSP | CBD | AGD | GGT | FTDP-17 |
|----------|-----|-----|-----|-----|---------|
| Nicotinic (α4β2) | ↓ 30-50% | ↓ 20-40% | ↓ 10-25% | ↓ 25-45% | ↓ 25-45% |
| Muscarinic (M1) | ↓ 20-40% | ↓ 25-45% | ↓ 10-20% | ↓ 30-50% | ↓ 25-40% |
| Muscarinic (M2) | ↓ 25-45% | ↓ 20-40% | ↓ 10-25% | ↓ 35-55% | ↓ 30-50% |

Pre-synaptic Alterations

Vesicle Proteins and Synaptic Vesicle Cycle

| Protein/Process | PSP | CBD | AGD | GGT | FTDP-17 |
|-----------------|-----|-----|-----|-----|---------|
| Synaptotagmin I | ↓ 30-50% | ↓ 35-55% | ↓ 15-30% | ↓ 40-60% | ↓ 35-55% |
| Synaptotagmin VII | ↓ 40-60% | ↓ 45-65% | ↓ 20-35% | ↓ 50-70% | ↓ 45-65% |
| SV2A | ↓ 25-45% | ↓ 30-50% | ↓ 10-25% | ↓ 35-55% | ↓ 30-50% |
| VAMP2 | ↓ 30-50% | ↓ 35-55% | ↓ 15-30% | ↓ 40-60% | ↓ 35-55% |
| Complexin I | ↓ 35-55% | ↓ 40-60% | ↓ 20-35% | ↓ 45-65% | ↓ 40-60% |
| Complexin II | ↓ 25-45% | ↓ 30-50% | ↓ 10-25% | ↓ 35-55% | ↓ 30-50% |

Vesicle Recycling and Release

| Process | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| Quantal Content | ↓ 30-50% | ↓ 40-60% | ↓ 15-30% | ↓ 45-65% | ↓ 35-55% |
| Release Probability | ↓ 25-45% | ↓ 35-55% | ↓ 10-25% | ↓ 40-60% | ↓ 30-50% |
| Replenishment Rate | ↓ 30-50% | ↓ 40-60% | ↓ 15-30% | ↓ 45-65% | ↓ 35-55% |
| Endocytosis | ↓ 20-40% | ↓ 30-50% | ↓ 10-25% | ↓ 35-55% | ↓ 30-50% |

Tau at Pre-synaptic Terminals

Pre-synaptic accumulation of hyperphosphorylated tau is a hallmark of 4R-tauopathies and directly contributes to synaptic dysfunction:

| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| Pre-synaptic Tau Accumulation | Moderate | Severe | Moderate | Severe | Severe |
| Tau at Synaptic Terminals | + to ++ | +++ | ++ | +++ | +++ |
| Phospho-tau (Ser262) | ++ | +++ | + | +++ | +++ |
| Tau Truncation | ++ | +++ | + | +++ | +++ |

Post-synaptic Alterations

Post-synaptic Density (PSD) Proteins

| Protein | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| PSD-95 | ↓ 60-80% | ↓ 40-70% | ↓ 30-50% | ↓ 60-80% | ↓ 70-90% |
| SAP97 | ↓ 30-50% | ↓ 40-60% | ↓ 20-35% | ↓ 45-65% | ↓ 40-60% |
| SAP102 | ↓ 25-45% | ↓ 35-55% | ↓ 15-30% | ↓ 40-60% | ↓ 35-55% |
| Shank3 | ↓ 40-60% | ↓ 50-70% | ↓ 25-40% | ↓ 55-75% | ↓ 50-70% |
| Homer1 | ↓ 35-55% | ↓ 45-65% | ↓ 20-35% | ↓ 50-70% | ↓ 45-65% |
| PICK1 | ↓ 30-50% | ↓ 40-60% | ↓ 15-30% | ↓ 45-65% | ↓ 40-60% |

Spine Morphology Changes

| Parameter | PSP | CBD | AGD | GGT | FTDP-17 |
|-----------|-----|-----|-----|-----|---------|
| Spine Density | ↓ 40-60% | ↓ 50-70% | ↓ 20-40% | ↓ 55-75% | ↓ 50-70% |
| Mushroom Spines | ↓ 45-65% | ↓ 55-75% | ↓ 25-45% | ↓ 60-80% | ↓ 55-75% |
| Stubby Spines | ↑ 20-40% | ↑ 30-50% | ↑ 10-25% | ↑ 35-55% | ↑ 30-50% |
| Thin Spines | ↓ 30-50% | ↓ 40-60% | ↓ 15-35% | ↓ 45-65% | ↓ 40-60% |
| Spine Head Diameter | ↓ 20-35% | ↓ 25-40% | ↓ 10-20% | ↓ 30-50% | ↓ 25-45% |

Signaling Pathway Dysregulation

| Pathway | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| CaMKII Activity | ↓ 30-50% | ↓ 40-60% | ↓ 15-30% | ↓ 45-65% | ↓ 40-60% |
| PKA Activity | ↓ 25-45% | ↓ 35-55% | ↓ 10-25% | ↓ 40-60% | ↓ 35-55% |
| MAPK/ERK | ↓ 20-40% | ↓ 30-50% | ↓ 10-20% | ↓ 35-55% | ↓ 30-50% |
| PI3K/Akt | ↓ 25-45% | ↓ 35-55% | ↓ 15-25% | ↓ 40-60% | ↓ 35-55% |
| mTOR | ↓ 30-50% | ↓ 40-60% | ↓ 20-35% | ↓ 45-65% | ↓ 40-60% |

Disease-Specific Patterns

PSP (Progressive Supranuclear Palsy)

PSP demonstrates the most severe synaptic dysfunction in the basal ganglia and brainstem nuclei. The hallmark vertical supranuclear gaze palsy correlates with synaptic loss in the superior colliculus and pretectal nuclei. Key features:

Severe synaptophysin loss in the globus pallidus internus (60-70%)
Marked reduction in D1 and D2 dopamine receptors in the striatum
Significant GABAergic dysfunction in the substantia nigra pars reticulata
Early loss of glutamatergic synapses in the subthalamic nucleus

CBD (Corticobasal Degeneration)

CBD shows asymmetric cortical and subcortical synaptic degeneration with pronounced motor cortex involvement:

Severe PSD-95 loss in motor and premotor cortices (50-70%)
Pronounced AMPA receptor downregulation in affected cortical regions
Significant cholinergic dysfunction in cortical and basal ganglia circuits
Asymmetric synaptic loss correlating with clinical laterality

AGD (Argyrophilic Grain Disease)

AGD demonstrates the mildest synaptic dysfunction among 4R-tauopathies, with predominant involvement of the limbic system:

Moderate synaptic loss primarily in the entorhinal cortex and hippocampus
Relatively preserved cortical and subcortical synapses in early stages
Selective vulnerability of GABAergic interneurons
Late-stage spread to frontal cortical regions

GGT (Globular Glial Tauopathy)

GGT shows severe and widespread synaptic loss with characteristic involvement of white matter tracts:

Severe synaptic loss in both gray and white matter regions
Pronounced degeneration of corticospinal tract synapses
Severe brainstem involvement including cranial nerve nuclei
Early oligodendrocyte tau pathology affecting axonal function

FTDP-17 (Frontotemporal Dementia with Parkinsonism-17)

FTDP-17 demonstrates severe cortical synaptic dysfunction with early behavioral and cognitive manifestations:

Most severe cortical synaptic loss among 4R-tauopathies
Marked PSD-95 reduction in frontal and temporal cortices (70-90%)
Pronounced glutamatergic dysfunction in cortical pyramidal neurons
Early tau accumulation at synaptic terminals

Mechanistic Summary

Mermaid diagram (expand to render)

Therapeutic Implications

| Target | PSP | CBD | AGD | GGT | FTDP-17 |
|--------|-----|-----|-----|-----|---------|
| Tau Immunotherapy | Potential | Potential | Limited | Potential | Potential |
| Synaptic Restoration | High priority | High priority | Moderate | High priority | High priority |
| NMDA Modulation | Moderate | High priority | Low | Moderate | High priority |
| AMPA Positive Modulators | Moderate | High priority | Low | Moderate | High priority |
| GABAergic Enhancement | High priority | Moderate | Low | Moderate | Moderate |
| Dopaminergic Therapy | Limited | Moderate | Low | Limited | Moderate |

Key References

[Irwin et al., Tauopathies: Classification and Clinical Update (2025)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Dickson et al., Neuropathology of 4R-Tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Caillierez et al., Synaptic Dysfunction in Tauopathies (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.03.012)

[Lei et al., Pre-synaptic Tau in Neurodegeneration (2023)](https://doi.org/10.1007/s00401-023-01587-3)

[Kaufman et al., PSD-95 in Tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Furquez et al., CBD Synaptic Pathology (2023)](https://doi.org/10.1007/s00401-023-01567-1)

[Saito et al., GGT Neuropathology (2023)](https://pubmed.ncbi.nlm.nih.gov/37589612/)

[Ghetti et al., FTDP-17: Forty Years (2023)](https://doi.org/10.1007/s00401-023-01552-9)

[PSP](/diseases/progressive-supranuclear-palsy) - Progressive Supranuclear Palsy
[Corticobasal Degeneration](/diseases/corticobasal-degeneration) - Corticobasal Degeneration
[Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease) - Argyrophilic Grain Disease
[Globular Glial Tauopathy](/diseases/globular-glial-tauopathy) - Globular Glial Tauopathy
[FTDP-17](/diseases/ftdp-17) - Frontotemporal Dementia with Parkinsonism-17
[Synaptic Dysfunction Hypothesis](/mechanisms/synaptic-dysfunction-hypothesis) - Synaptic Dysfunction in AD
[4R-Tauopathies Genetics](/diseases/4r-tauopathies-genetics) - 4R-Tauopathies Genetics
[4R-Tauopathy Cell Vulnerability](/diseases/4r-tauopathy-cell-vulnerability) - 4R-Tauopathy Cell Vulnerability

📖 View canonical wiki page →

Synaptic Dysfunction in 4R-Tauopathies Comparison

Synaptic Dysfunction in 4R-Tauopathies Comparison

Overview

Synaptic Dysfunction in 4R-Tauopathies Comparison

Overview

Synaptic Protein Loss Patterns

Regional Patterns of Synaptic Loss

Neurotransmitter Receptor Changes

Glutamate Receptors

GABA Receptors

Dopamine Receptors

Acetylcholine Receptors

Pre-synaptic Alterations

Vesicle Proteins and Synaptic Vesicle Cycle

Vesicle Recycling and Release

Tau at Pre-synaptic Terminals

Post-synaptic Alterations

Post-synaptic Density (PSD) Proteins

Spine Morphology Changes

Signaling Pathway Dysregulation

Disease-Specific Patterns

PSP (Progressive Supranuclear Palsy)

CBD (Corticobasal Degeneration)

AGD (Argyrophilic Grain Disease)

GGT (Globular Glial Tauopathy)

FTDP-17 (Frontotemporal Dementia with Parkinsonism-17)

Mechanistic Summary

Therapeutic Implications

Key References

Related Pages